Sands Capital Management LLC Buys Shares of 16,625 argenex SE $ARGX

Sands Capital Management LLC purchased a new position in argenex SE (NASDAQ:ARGX) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 16,625 shares of the company’s stock, valued at approximately $12,262,000.

Other large investors have also made changes to their positions in the company. Sound View Wealth Advisors Group LLC raised its stake in argenex by 3.4% in the 3rd quarter. Sound View Wealth Advisors Group LLC now owns 396 shares of the company’s stock valued at $292,000 after purchasing an additional 13 shares during the last quarter. GAMMA Investing LLC lifted its position in argenex by 6.8% during the third quarter. GAMMA Investing LLC now owns 251 shares of the company’s stock worth $185,000 after buying an additional 16 shares during the period. Portside Wealth Group LLC boosted its stake in argenex by 2.8% in the 3rd quarter. Portside Wealth Group LLC now owns 583 shares of the company’s stock worth $430,000 after buying an additional 16 shares during the last quarter. Cromwell Holdings LLC grew its holdings in argenex by 10.0% in the 3rd quarter. Cromwell Holdings LLC now owns 187 shares of the company’s stock valued at $138,000 after buying an additional 17 shares during the period. Finally, Wealth Alliance LLC increased its stake in shares of argenex by 2.7% during the 3rd quarter. Wealth Alliance LLC now owns 839 shares of the company’s stock valued at $619,000 after acquiring an additional 22 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Zacks Research raised shares of argenex from a “strong sell” rating to a “hold” rating in a research report on Friday, February 20th. Stifel Nicolaus upped their price target on shares of argenex from $1,028.00 to $1,248.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Robert W. Baird lifted their price target on shares of argenex from $858.00 to $867.00 and gave the company a “neutral” rating in a report on Friday, February 27th. Citigroup lowered their price objective on shares of argenex from $1,124.00 to $1,091.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. Finally, Citizens Jmp increased their target price on argenex from $925.00 to $944.00 and gave the stock a “market outperform” rating in a research report on Friday, February 27th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $999.22.

argenex Stock Up 0.3%

ARGX opened at $742.79 on Wednesday. argenex SE has a 52-week low of $510.05 and a 52-week high of $934.62. The company has a 50 day moving average of $811.69 and a two-hundred day moving average of $817.18. The company has a market cap of $45.96 billion, a P/E ratio of 38.05, a P/E/G ratio of 1.22 and a beta of 0.38.

argenex (NASDAQ:ARGX) last posted its earnings results on Thursday, February 26th. The company reported $8.02 earnings per share for the quarter, beating the consensus estimate of $6.05 by $1.97. argenex had a net margin of 30.42% and a return on equity of 38.51%. The business had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.30 billion. Research analysts anticipate that argenex SE will post 3.13 earnings per share for the current year.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.